pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›povetacicept
drug · protein
save

povetacicept

Phase 3updated 3mo ago
by $VERX Vertex, Inc.🔗 ChEMBL
Phase 3
community read0 votes

Protein drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying povetacicept

  • phase2A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravisrecruitingn=30
  • phase3Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)recruitingn=176
  • phase3Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)active not recruitingn=605
  • phase2An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseasesactive not recruitingn=72
  • phase1A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentationscompletedn=136
  • phase2An Open-label Study of Povetacicept in Participants With Autoimmune Cytopeniasactive not recruitingn=30

News(4)

  • Vertex unfazed by competitive IgAN space as FDA verdict looms
    Positive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said…
    biospace · 7d ago
  • Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
    The FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for…
    biospace · 22d ago
  • 10 clinical trials to watch in the second half of 2026
    The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
    biopharma_dive · 1mo ago
  • Vertex earnings get muted investor response
    While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.
    biopharma_dive · 3mo ago
trade names
Variant tnf receptor domain
generic
povetacicept
indication
Membranous Glomerulonephritis
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 49m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?